SPOTLIGHT: Pfizer to disclose grants, donations

Pfizer is pledging "greater transparency" in its dealings with medical, scientific, and patient organizations; its first step is disclosing all grants and charitable contributions for the first quarter of this year. Release | Report

Suggested Articles

Pfizer’s Ibrance has met with success in breast cancer since breaking onto the scene in 2015. But its first foray into early breast cancer was a bust.

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.